Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5475-5480

  Okuda, Kentaro ^a   Hirose, Takashi ^a   Oki, Yasunari ^a   Murata, Yasunori ^a   Kusumoto, Sojiro ^a   Sugiyama, Tomohide ^a   Ishida, Hiroo ^a   Shirai, Takao ^a   Nakashima, Masanao ^a   Yamaoka, Toshimitsu ^a   Ohnishi, Tsukasa ^a   Ohmori, Tohru ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute exacerbation; Interstitial lung disease; Lung cancer; Platinum agent; Vinorelbine

Indexed keywords

C REACTIVE PROTEIN; CARBOPLATIN; CISPLATIN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; NAVELBINE;

ADULT; ADVANCED CANCER; ANEMIA; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; HYPOXIA; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VINBLASTINE;

EID: 84872569535     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bouros D, Hatzakis K, Labrakis H and Zeibecoglou K: Association of malignancy with diseases causing interstitial pulmonary changes. Chest 121: 1278-1289, 2002.
2. Hubbard R, Venn A, Lewis S and Britton J: Lung cancer and cryptogenic fibrosing alveolitis: A population-based cohort study. Am J Respir Crit Care Med 161: 5-8, 2000.
3. Raghu G, Nyberg F and Morgan G: The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 91: S3-S10, 2004.
4. Hyzy R, Huang S, Myers J, Flaherty K and Martinez F: Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132: 1652-1658, 2007.
5. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K and Takagi K: Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 103: 1808-1812, 1993.
6. Akira M, Hamada H, Sakatani M, Kobayashi C, Nishioka M and Yamamoto S: CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis. Am J Roentgenol 168: 79-93, 1997.
7. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, Hashizume H, Naito T, Hashimoto T, Takehara Y, Inui N, Nakamura H, Colby TV and Chida K: Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir Med 103: 846-853, 2009.
8. Kim DS, Park JH, Park BK, Lee JS, Nicholson AG and Colby TV: Acute exacerbation of idiopathic pulmonary fibrosis: Frequency and clinical features. Eur Respir J 27: 143-150, 2006.
9. Park IN, Kim DS, Shim TS, Lim CM, Lee SD, Koh Y, Kim WS, Kim WD, Jang SJ and Colby TV: Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest 132: 214-220, 2007.
10. Chiyo M, Sekine Y, Iwata T, Tatsumi K, Yasufuku K, Iyoda A, Otsuji M, Yoshida S, Shibuya K, Iizasa T, Saitoh Y and Fujisawa T: Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: Analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 126: 1141-1146, 2003.
11. Kushibe K, Kawaguchi T, Takahama M, Kimura M, Tojo T and Taniguchi S: Operative indications for lung cancer with idiopathic pulmonary fibrosis. Thorac Cardiovasc Surg 55: 505-508, 2007.
12. Minegishi Y, Takenaka K, Mizutani H, Sudoh J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, Kudoh S and Gemma A: Excerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 48: 665-672, 2009.
13. Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K and Homma S: Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anticancer therapy. Respirology 15: 88-92, 2010.
14. Watanabe N, Taniguchi H, Kondoh Y, Kimura T and Kataoka K: Clinical characteristics of advanced non-small cell lung cancer patients with interstitial pneumonia. Japanese Journal of Lung Cancer 51: 171-176, 2011 (in Japanese).
15. Shukuya T, Ishiwata T, Hara M, Muraki K, Shibayama R, Koyama R and Takahashi K: Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30: 4357-4361, 2010.
16. Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, Yoshimura A, Kudoh S and Gemma A: The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71: 70-74, 2011.
17. Bretti S, Manzin E, Celano A, Ritorto G, Loddo C and Berruti A: Low dose carboplatin (AUC 4.5) combined with vinorelbine in the treatment of advanced non-small cell lung cancer: A single institution phase II study. Oncol Rep 8: 381-385, 2001.
18. Cremonesi M, Mandala M, Cazzaniga M, Rezzani C, Gambera M and Barni S: Vinorelbine and carboplatin in inoperable non-small cell lung cancer: A monoinstitutional phase II study. Oncology 64: 97-101, 2003.
19. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007.
20. Demedts M and Costabel U: ATS/ERS International Multidisciplinary Consensus Classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165: 277-304, 2002.
21. Raghu G, Mageto YN, Lockhart D, Schmidt RA, Wood DE and Godwin JD: The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study. Chest 116: 1168-1174, 1999.
22. Johkoh T, Muller NL, Cartier Y, Kavanagh PV, Akira M, Ichikado K, Ando M and Nakamura H: Idiopathic interstitial pneumonias: Diagnostic accuracy of thin-section CT in 129 patients. Radiology 211: 555-560, 1999.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
24. National Cancer Institute of the United States: Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. http://ctep.cancer.gov/ reporting/ctc.html.
25. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, Japan Thoracic Radiology Group, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T and Nyberg F: Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case control study. Am J Respir Crit Care Med 177: 1348-1357, 2008.
26. Camus P, Fanton A, Bonniaud P, Camus C and Foucher P: Interstitial lung disease induced by drugs and radiation. Respiration 71: 301-326, 2004.
27. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R and Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355: 2542-2550, 2006.
28. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gandara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
29. Azzoli CG, Baker Jr S, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D and Giaccone G: American Society of Clinical Oncology Clinical Practice Guideline Update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 27: 6251-6266, 2009.